S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+11.11%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)
S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+11.11%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)
S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+11.11%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)
S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+11.11%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)

Enliven Therapeutics (ELVN) News Today

$11.99
+0.74 (+6.58%)
(As of 12/8/2023 ET)
Compare
Today's Range
$11.01
▼
$12.54
50-Day Range
$10.40
▼
$14.42
52-Week Range
$9.98
▼
$25.34
Volume
89,452 shs
Average Volume
127,128 shs
Market Capitalization
$494.11 million
P/E Ratio
3.75
Dividend Yield
N/A
Price Target
$27.00
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media
SourceHeadline
benzinga.com logoEnliven Therapeutics Stock (NASDAQ:ELVN) Earnings Dates and Earning Calls
benzinga.com - November 11 at 6:44 PM
finanznachrichten.de logoEnliven Therapeutics, Inc.: Enliven Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
finanznachrichten.de - November 10 at 10:51 AM
markets.businessinsider.com logoAnalysts Offer Insights on Healthcare Companies: Senseonics Holdings (SENS) and Enliven Therapeutics (ELVN)
markets.businessinsider.com - November 10 at 10:51 AM
msn.com logoEnliven Therapeutics GAAP EPS of -$0.51
msn.com - November 9 at 6:06 PM
finance.yahoo.com logoEnliven Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
finance.yahoo.com - November 9 at 6:06 PM
morningstar.com logoEnliven Therapeutics Inc ELVN
morningstar.com - November 9 at 1:06 PM
seekingalpha.com logoEnliven Therapeutics 10% owner disposes of ~$3M worth of shares
seekingalpha.com - October 1 at 10:53 PM
marketbeat.com logoEnliven Therapeutics, Inc. (NASDAQ:ELVN) Major Shareholder Sells $2,962,500.00 in Stock
marketbeat.com - September 29 at 3:20 PM
benzinga.com logoEnliven Therapeutics Insider Trades Send a Signal
benzinga.com - September 29 at 1:25 PM
marketbeat.com logo9,900 Shares in Enliven Therapeutics, Inc. (NASDAQ:ELVN) Acquired by Denali Advisors LLC
marketbeat.com - September 29 at 6:43 AM
marketbeat.com logoPrelude Capital Management LLC Buys New Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN)
marketbeat.com - September 22 at 4:16 AM
marketbeat.com logoFairmount Funds Management LLC Acquires New Shares in Enliven Therapeutics, Inc. (NASDAQ:ELVN)
marketbeat.com - September 12 at 12:39 PM
marketbeat.com logoMirabella Financial Services LLP Invests $256,000 in Enliven Therapeutics, Inc. (NASDAQ:ELVN)
marketbeat.com - September 6 at 9:26 AM
seekingalpha.com logoEnliven Therapeutics: Preclinical Company With Interesting Value Proposition
seekingalpha.com - August 18 at 12:57 PM
finance.yahoo.com logoFairmount Funds Management LLC Acquires New Stake in Kiniksa Pharmaceuticals Ltd
finance.yahoo.com - August 11 at 5:45 PM
finanznachrichten.de logoEnliven Therapeutics, Inc.: Enliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
finanznachrichten.de - August 11 at 5:32 AM
finance.yahoo.com logoEnliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
finance.yahoo.com - August 10 at 4:46 PM
finance.yahoo.com logoEnliven Therapeutics to Present at Two Upcoming Investor Conferences
finance.yahoo.com - May 31 at 5:37 PM
markets.businessinsider.com logoAnalysts Offer Insights on Healthcare Companies: ProKidney (PROK) and Enliven Therapeutics (ELVN)
markets.businessinsider.com - May 12 at 8:49 AM
finance.yahoo.com logoEnliven Therapeutics Highlights Business Achievements and Reports First Quarter 2023 Financial Results
finance.yahoo.com - May 11 at 5:48 PM
investing.com logoEnliven Therapeutics Inc (ELVN)
investing.com - April 6 at 8:33 PM
wsj.com logoEnliven Therapeutics Inc.
wsj.com - March 1 at 2:34 PM
nasdaq.com logoEnliven Therapeutics, Inc. Common Stock (ELVN)
nasdaq.com - March 1 at 2:34 PM
Get Enliven Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ELVN and its competitors with MarketBeat's FREE daily newsletter.



ELVN Media Mentions By Week

ELVN Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ELVN
News Sentiment
▼
0.00

0.51
▲
Average
Medical
News Sentiment

ELVN News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ELVN Articles
This Week
▼
0

0
▲
ELVN Articles
Average Week

Get Enliven Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ELVN and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies:
Headlines Tools:
This page (NASDAQ:ELVN) was last updated on 12/8/2023 by MarketBeat.com Staff

My Account -